2023
The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease
DeBroff J, Omer N, Cohen B, Giladi N, Kestenbaum M, Shirvan J, Cedarbaum J, Gana‐Weisz M, Goldstein O, Orr‐Urtreger A, Mirelman A, Thaler A. The Influence of GBA and LRRK2 on Mood Disorders in Parkinson's Disease. Movement Disorders Clinical Practice 2023, 10: 606-616. PMID: 37070047, PMCID: PMC10105114, DOI: 10.1002/mdc3.13722.Peer-Reviewed Original ResearchDiagnosis of PDParkinson's diseaseMood-related disordersTime of assessmentMood disordersIdiopathic PDNon-motor comorbiditiesNon-motor featuresIdiopathic Parkinson's diseaseNon-motor phenotypeFrequency of depressionMood related disordersState of depressionPD patientsSuch medicationsWorse motorGenetic statusMedicationsProdromal stageRelated disordersGBA genePD diagnosisDiseaseDiagnosisDisorders
2011
Revision of the criteria for Alzheimer's disease: A symposium
DeKosky ST, Carrillo MC, Phelps C, Knopman D, Petersen RC, Frank R, Schenk D, Masterman D, Siemers ER, Cedarbaum JM, Gold M, Miller DS, Morimoto BH, Khachaturian AS, Mohs RC. Revision of the criteria for Alzheimer's disease: A symposium. Alzheimer's & Dementia 2011, 7: e1-e12. PMID: 21322828, DOI: 10.1016/j.jalz.2010.12.007.Peer-Reviewed Original ResearchConceptsAlzheimer's diseaseClinical diagnosisRelated Disorders Association criteriaAlzheimer's Association Research RoundtableDefinitive clinical diagnosisCurrent diagnostic criteriaPotential diagnostic biomarkersPresymptomatic Alzheimer's diseaseCurrent standardMild cognitive impairmentClinical presentationAD pathologyClinicopathologic correlationAssociation criteriaDiagnostic criteriaMild stageCognitive impairmentDiagnostic biomarkersCommunicative DisordersResearch RoundtableDiseaseBetter ascertainmentGenetics of ADCurrent criteriaDiagnosis
1991
"Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
Cedarbaum JM, Gandy SE, McDowell FH. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease. Neurology 1991, 41: 622-9. PMID: 2027475, DOI: 10.1212/wnl.41.5.622.Peer-Reviewed Original ResearchConceptsMotor response fluctuationsLevodopa therapyLevodopa treatmentDisease clinicResponse fluctuationsParkinson's disease clinicDevelopment of dyskinesiaHistory of patientsTiming of initiationPatient populationDisease onsetParkinson's diseaseDyskinesiaYounger ageDementiaPatientsTherapyAdverse consequencesTreatmentDiseaseGreater proportionInitiationDisease diagnosisClinicDiagnosis